Literature DB >> 15668445

Mutations in the acid alpha-glucosidase gene (M. Pompe) in a patient with an unusual phenotype.

J M H Anneser1, D E Pongratz, T Podskarbi, Y S Shin, B G H Schoser.   

Abstract

Glycogenosis type II (Pompe disease) is a lysosomal storage disease caused by deficiency of acid alpha-glucosidase (acid maltase). The disease is autosomal recessive inherited and is clinically and genetically heterogenous. The authors describe a 30-year-old woman affected by late-onset Pompe disease with vascular affection resembling atherosclerotic angiopathy of the elderly. Genetic analysis revealed two novel mutations (Ala237Val and Gly293Arg) in the acid alpha-glucosidase gene in this patient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15668445     DOI: 10.1212/01.WNL.0000149528.95362.20

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

1.  Pompe disease presenting as an isolated generalized dilative arteriopathy with repeated brain and kidney infarcts.

Authors:  Véronique Quenardelle; Marc Bataillard; Dorothée Bazin; Béatrice Lannes; Valérie Wolff; Andoni Echaniz-Laguna
Journal:  J Neurol       Date:  2014-12-02       Impact factor: 4.849

2.  Late-onset Pompe disease: a genetic-radiological correlation on cerebral vascular anomalies.

Authors:  A Pichiecchio; S Sacco; P De Filippi; E Caverzasi; S Ravaglia; S Bastianello; C Danesino
Journal:  J Neurol       Date:  2017-08-30       Impact factor: 4.849

3.  Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease.

Authors:  Manuela Corti; Cristina Liberati; Barbara K Smith; Lee Ann Lawson; Ibrahim S Tuna; Thomas J Conlon; Kirsten E Coleman; Saleem Islam; Roland W Herzog; David D Fuller; Shelley W Collins; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2017-12       Impact factor: 5.032

4.  Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD).

Authors:  Federica Montagnese; Francesca Granata; Olimpia Musumeci; Carmelo Rodolico; Stefania Mondello; Emanuele Barca; Maria Cucinotta; Anna Ciranni; Marcello Longo; Antonio Toscano
Journal:  J Inherit Metab Dis       Date:  2016-02-01       Impact factor: 4.982

5.  Pompe disease diagnosis and management guideline.

Authors:  Priya S Kishnani; Robert D Steiner; Deeksha Bali; Kenneth Berger; Barry J Byrne; Laura E Case; Laura Case; John F Crowley; Steven Downs; R Rodney Howell; Richard M Kravitz; Joanne Mackey; Deborah Marsden; Anna Maria Martins; David S Millington; Marc Nicolino; Gwen O'Grady; Marc C Patterson; David M Rapoport; Alfred Slonim; Carolyn T Spencer; Cynthia J Tifft; Michael S Watson
Journal:  Genet Med       Date:  2006-05       Impact factor: 8.822

6.  Renal artery fibromuscular dysplasia in Pompe disease: A case report.

Authors:  Evangelia Pappa; Constantinos Papadopoulos; Philippe Grimbert; Pascal Laforêt; Guillaume Bassez
Journal:  Mol Genet Metab Rep       Date:  2018-07-26

7.  GAA compound heterozygous mutations associated with autophagic impairment cause cerebral infarction in Pompe disease.

Authors:  Xiaodong Jia; Libin Shao; Chengcheng Liu; Tuanzhi Chen; Ling Peng; Yinguang Cao; Chuanchen Zhang; Xiafeng Yang; Guifeng Zhang; Jianlu Gao; Guangyi Fan; Mingliang Gu; Hongli Du; Zhangyong Xia
Journal:  Aging (Albany NY)       Date:  2020-03-03       Impact factor: 5.682

8.  Glycogen accumulation in smooth muscle of a Pompe disease mouse model.

Authors:  Angela L McCall; Justin S Dhindsa; Aidan M Bailey; Logan A Pucci; Laura M Strickland; Mai K ElMallah
Journal:  J Smooth Muscle Res       Date:  2021

9.  Distinct disease phenotypes linked to different combinations of GAA mutations in a large late-onset GSDII sibship.

Authors:  Simone Sampaolo; Teresa Esposito; Olimpia Farina; Daniela Formicola; Daria Diodato; Fernando Gianfrancesco; Federica Cipullo; Gaetana Cremone; Mario Cirillo; Luca Del Viscovo; Antonio Toscano; Corrado Angelini; Giuseppe Di Iorio
Journal:  Orphanet J Rare Dis       Date:  2013-10-10       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.